Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial

被引：0

作者：

Li Zhang

Xin Mei

Zhigang Hu

Bo Yu

Chaoyang Zhang

Yong Li

Kaitai Liu

Xuejun Ma

Jinli Ma

Xingxing Chen

Jin Meng

Wei Shi

Xiaofang Wang

Miao Mo

Zhimin Shao

Zhen Zhang

Xiaoli Yu

Xiaomao Guo

Zhaozhi Yang

机构：

[1] Fudan University Shanghai Cancer Center,Department of Radiation Oncology

[2] Fudan University,Department of Oncology, Shanghai Medical College

[3] Shanghai Key Laboratory of Radiation Oncology,Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine

[4] University of Science and Technology of China,Department of Radiotherapy

[5] the Affiliated Jiangyin Hospital of Nantong University,Department of Radiation Oncology

[6] The First Hospital of Quanzhou Affiliated to Fujian Medical University,Department of Oncology

[7] Guizhou Provincial People’s Hospital,Department of Radiation Oncology

[8] The Affiliated Lihuili Hospital of Ningbo University,Department of Cancer Prevention & Clinical Statistics Center

[9] Fudan University Shanghai Cancer Center,Department of Breast Surgery

[10] Fudan University Shanghai Cancer Center,Key Laboratory of Breast Cancer in Shanghai

[11] Fudan University Shanghai Cancer Center,Department of Medical Oncology

[12] Kashgar Prefecture Second People ’ s Hospital,undefined

[13] Xinjiang Uyghur Autonomous Region,undefined

来源：

BMC Cancer | / 24卷

关键词：

Breast cancer; Supraclavicular nodal irradiation; Target volume; Survival outcome; Toxicity;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
Kyung-Ha Lee
In Jun Yang
Gi Won Ha
Jaeim Lee
Youn Young Park
Suk Hwan Lee
Jong Min Lee
Jung Hoon Bae
Eun Jung Park
Hyungjin Kim
Keun Young Kim
Sanghyung An
Ik Yong Kim
Ji Yeon Kim
BMC Cancer, 24
[22] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
Lee, Kyung-Ha
Yang, In Jun
Ha, Gi Won
Lee, Jaeim
Park, Youn Young
Lee, Suk Hwan
Lee, Jong Min
Bae, Jung Hoon
Park, Eun Jung
Kim, Hyungjin
Kim, Keun Young
An, Sanghyung
Kim, Ik Yong
Kim, Ji Yeon
BMC CANCER, 2024, 24 (01)
[23] Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Ellis, Paul
Barrett-Lee, Peter
Johnson, Lindsay
Cameron, David
Wardley, Andrew
O'Reilly, Susan
Verrill, Mark
Smith, Ian
Yarnold, John
Coleman, Robert
Earl, Helena
Canney, Peter
Twelves, Chris
Poole, Christopher
Bloomfield, David
Hopwood, Penelope
Johnston, Stephen
Dowsett, Mitchell
Bartlett, John M. S.
Ellis, Ian
Peckitt, Clare
Hall, Emma
Bliss, Judith M.
LANCET, 2009, 373 (9676): : 1681 - 1692
[24] MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer
Rastogi, Priya
Toi, Masakazu
Harbeck, Nadia
Bourayou, Nawel
Frenzel, Martin
Johnston, Stephen
CANCER RESEARCH, 2018, 78 (04)
[25] Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicenter, open-label, randomized phase III controlled trial, the MIRO trial
Mariette, Christophe
Meunier, Bernard
Pezet, Denis
Dalban, Cecile
Collet, Denis
Thomas, Pascal-Alexandre
Brigand, Cecile
Perniceni, Thierry
Carrere, Nicolas
Bonnetain, Franck
Piessen, Guillaume
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[26] Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial.
Park, Jun Seok
Park, Soo Yeun
Choi, Gyu-Seog
Kim, Hye Jin
Kim, Jong Gwang
Kang, Byung Woog
Lee, In Kyu
Lee, Yoon Suk
Kim, Sohyun
Baek, Seong Kyu
Son, Gyung Mo
Bae, Ki Beom
Kim, Ji Yeon
Lee, Kyung-ha
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[27] Comparison of D2 vs D3 lymph node dissection for RIght COloN cancer (RICON): study protocol for an international multicenter open-label randomized controlled trial
Balaban, Vladimir
Mutyk, Mikhail
Bondarenko, Nikolay
Zolotukhin, Stanislav
Sovpel, Oleg
Sovpel, Igor
Zykov, Dmitriy
Rublevskiy, Igor
Klochkov, Mikhail
Prado, Alfredo Ponce
He, Mingze
Tsarkov, Petr
TRIALS, 2024, 25 (01)
[28] A multicenter, open-label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high-risk, early breast cancer (HRBC)
Recchia, Francesco
Candeloro, Giampiero
Cesta, Alisia
Desideri, Giovambattista
Necozione, Stefano
Rea, Silvio
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[29] Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial
de Vries, Kim C.
Wortel, Ruud C.
Oomen-de Hoop, Esther
Heemsbergen, Wilma D.
Pos, Floris J.
Incrocci, Luca
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (01): : 108 - 115
[30] Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial
Schmidt, Marcus
Nitz, Ulrike
Reimer, Toralf
Schmatloch, Sabine
Graf, Heiko
Just, Marianne
Stickeler, Elmar
Untch, Michael
Runnebaum, Ingo
Belau, Antje
Huober, Jens
Jackisch, Christian
Hofmann, Manfred
Krocker, Jutta
Nekljudova, Valentina
Loibl, Sibylle
EUROPEAN JOURNAL OF CANCER, 2023, 194

← 1 2 3 4 5 →